TaiMed Biologics Inc. Stock price

Equities

4147

TW0004147004

Biotechnology & Medical Research

End-of-day quote Taipei Exchange 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
88 TWD -0.11% Intraday chart for TaiMed Biologics Inc. -1.57% +7.32%
Sales 2024 * 977M 30.56M Sales 2025 * 1.95B 60.94M Capitalization 22.26B 696M
Net income 2024 * 33M 1.03M Net income 2025 * 960M 30.02M EV / Sales 2024 * 21.9 x
Net cash position 2024 * 824M 25.76M Net cash position 2025 * 1.79B 55.88M EV / Sales 2025 * 10.5 x
P/E ratio 2024 *
716 x
P/E ratio 2025 *
23.2 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 65.84%
More Fundamentals * Assessed data
Dynamic Chart
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Taimed Biologics and AcedrA Biopharmaceticals Partner to Commercialize Trogarzo in the Middle East and North Africa Region CI
Taimed Announces Its Marketing Partner Received Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from the US FDA CI
TaiMed Biologics Inc. Receives Patent Approval from the Taiwan Intellectual Property Office for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology CI
TaiMed Biologics Inc. Announces US FDA Grants Fast Track Designation to TMB-365/TMB-380 Long-Acting Combination Therapy for HIV Infection CI
TaiMed Biologics Inc. Revises the Phase 2 Clinical Study Design of Bi-Monthly Dosing of TMB-365/TMB-380 Combination for the Treatment of HIV Infection CI
Taimed Biologics Inc. Announces US FAD Approves the sBLA for the IV Push Administration of the Loading Dose of Trogarzo CI
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Theratechnologies Reports Results from Trogarzo Intramuscular Administration Study; Tesamorelin Poster Presentation MT
TaiMed Biologics Inc. Announces Results from Trogarzo Intramuscular (IM) Administration Study CI
TaiMed Biologics Inc. Completes Data Analysis of the Clinical Trial Sentinel Group for the TMB-365 and TMB-380 Combination as Expected and Confirms the Dosing for Future Execution CI
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
TaiMed Biologics Inc. Completes the Last Patient Visit of the Sentinel Group in the Clinical Study Evaluating Long-Acting TMB-365/TMB-380 Combination Maintenance Therapy CI
TaiMed Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
More news
1 day-0.11%
1 week-1.57%
Current month-20.36%
1 month-22.81%
3 months+6.80%
Current year+7.32%
More quotes
1 week
87.50
Extreme 87.5
89.80
1 month
87.50
Extreme 87.5
113.50
Current year
81.70
Extreme 81.7
116.50
1 year
76.30
Extreme 76.3
135.00
3 years
52.20
Extreme 52.2
135.00
5 years
52.20
Extreme 52.2
174.00
10 years
1.05
Extreme 1.05
349.50
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 08-05-31
Chairman - 09-06-11
Members of the board TitleAgeSince
Director/Board Member 66 -
Director/Board Member 66 18-09-06
Chairman - 09-06-11
More insiders
Date Price Change Volume
24-03-27 88 -0.11% 945,511
24-03-26 88.1 +0.34% 880,294
24-03-25 87.8 -1.13% 1,229,124
24-03-22 88.8 +0.23% 1,002,625
24-03-21 88.6 -0.89% 1,081,945

End-of-day quote Taipei Exchange, March 26, 2024

More quotes
TaiMed Biologics Inc. is a Taiwan-based company principally engaged in the research and development of new medicines. The Company mainly provides ibalizumab (TMB-355) and TMB-360, which are applied in the treatment of acquired immune deficiency syndrome (AIDS), and protease inhibitor (TMB-607), which is applied as pro-drugs for AIDS. The Company's ibalizumab is a humanized monoclonal antibody, which can interfere with the penetration of the virus into the cell. Its protease inhibitor uses nanotechnology formulation for subcutaneous and/or intramuscular injections.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
88 TWD
Average target price
129 TWD
Spread / Average Target
+46.61%
Consensus
  1. Stock
  2. Equities
  3. Stock TaiMed Biologics Inc. - Taipei Exchange